文献速递免疫规划妇幼与学校卫生传染病防控与疫情报告

评估塞拉利昂2018年常规儿童乙肝免疫规划的影响及乙肝疫苗出生剂次的需求

Assessing the impact of the routine childhood hepatitis B immunization program and the need for hepatitis B vaccine birth dose in Sierra Leone, 2018.
PubMed 文献 · Vaccine · 2022-03-28

在塞拉利昂三个区开展社区血清学调查,4-30月龄儿童HepB3覆盖率85%、HBsAg阳性率1.3%,5-9岁儿童覆盖率77%、阳性率1.6%,母亲HBsAg阳性率9.8%;儿童HBsAg阳性与母亲HBsAg阳性、HBeAg及HBV DNA≥200000 IU/mL相关,提示常规婴儿乙肝疫苗降低了HBV负担,但HepB-BD可能预防母婴传播。

要点

  • 4-30月龄儿童HepB3覆盖率85%,HBsAg阳性率1.3%(95%CI 0.8-2.0)。
  • 5-9岁儿童HepB3覆盖率77%,HBsAg阳性率1.6%(95%CI 1.1-2.3)。
  • 母亲HBsAg阳性者子女HBsAg阳性率5.9%,高于母亲阴性者的0.7%(调整OR=10.6,95%CI 2.8-40.8)。

核心结论

  • 儿童HBsAg阳性率低于未接种乙肝疫苗的母亲,提示常规婴儿乙肝疫苗接种已降低HBV负担。
  • 儿童HBsAg阳性与母亲HBV感染强烈相关,且多数HBsAg阳性儿童曾接种HepB3,HepB-BD可能预防母婴传播和慢性HBV感染。

研究设计与样本

  • 在塞拉利昂三个区开展基于社区的血清学调查,对象为4-30月龄儿童及其母亲和5-9岁儿童。
  • 参与者接受HBsAg快速检测,所有HBsAg阳性母亲及每个社区随机抽取一名HBsAg阴性母亲检测HBV标志物,并收集儿童HepB3接种史。

主要发现

  • 1889名4-30月龄儿童中,HepB3覆盖率为85%,20名(1.3%[95%CI 0.8-2.0])HBsAg阳性,其中70%曾接种HepB3。
  • 2025名5-9岁儿童中,HepB3覆盖率为77%,32名(1.6%[95%CI 1.1-2.3])HBsAg阳性,其中56%曾接种HepB3。
  • 1776名母亲中,169名(9.8%[95%CI 8.1-11.7])HBsAg阳性。
  • HBsAg阳性母亲子女的HBsAg阳性率为5.9%,HBsAg阴性母亲子女为0.7%(调整OR=10.6[95%CI 2.8-40.8])。
  • 儿童HBsAg阳性与母亲HBsAg(p=0.026)、HBeAg(p<0.001)及HBV DNA≥200000 IU/mL(p<0.001)相关。

关键数值与推荐

  • 塞拉利昂推荐自6周龄起接种三剂乙肝疫苗(HepB3),不推荐出生剂次(HepB-BD)。
  • 4-30月龄儿童HepB3覆盖率85%,HBsAg阳性率1.3%(95%CI 0.8-2.0)。
  • 5-9岁儿童HepB3覆盖率77%,HBsAg阳性率1.6%(95%CI 1.1-2.3)。
  • 母亲HBsAg阳性率9.8%(95%CI 8.1-11.7)。
  • 母亲HBsAg阳性者子女HBsAg阳性率5.9%,母亲阴性者子女0.7%(调整OR=10.6[95%CI 2.8-40.8])。

临床怎么用

  • 塞拉利昂现行推荐自6周龄起接种三剂乙肝疫苗,不推荐出生剂次。
  • 作者认为HepB-BD可能预防母婴传播和慢性HBV感染。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sierra Leone is highly endemic for hepatitis B virus (HBV) infection and thus recommends three doses of hepatitis B vaccine (HepB3) from 6 weeks of age but does not recommend a birth dose (HepB-BD) to prevent mother-to-child transmission (MTCT). We evaluated impact of the existing HepB3 schedule and risk for MTCT of HBV. We conducted a community-based serosurvey among 4-30-month-olds, their mothers, and 5-9-year-olds in three districts in Sierra Leone. Participants had an HBV surface antigen (HBsAg) rapid test; all HBsAg-positive and one HBsAg-negative mother per cluster were tested for HBV markers. We collected children's HepB3 vaccination history. Among 1889 children aged 4-30 months, HepB3 coverage was 85% and 20 (1·3% [95% CI 0·8-2·0]) were HBsAg-positive, of whom 70% had received HepB3. Among 2025 children aged 5-9 years, HepB3 coverage was 77% and 32 (1·6% [1·1-2·3]) were HBsAg-positive, of whom 56% had received HepB3. Of 1776 mothers, 169 (9·8% [8·1-11·7]) were HBsAg-positive. HBsAg prevalence was 5·9% among children of HBsAg-positive mothers compared to 0·7% among children of HBsAg-negative mothers (adjusted OR = 10·6 [2·8-40·8]). HBsAg positivity in children was associated with maternal HBsAg (p = 0·026), HBV e antigen (p < 0·001), and HBV DNA levels ≥ 200 000 IU/mL (p < 0·001). HBsAg prevalence was lower among children than mothers, for whom HepB was not available, suggesting routine infant HepB vaccination has lowered HBV burden. Since HBsAg positivity in children was strongly associated with maternal HBV infection and most of the HBsAg-positive children in the survey received HepB3, HepB-BD may prevent MTCT and chronic HBV infection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Breakwell L, Marke D, Kaiser R, et al. Assessing the impact of the routine childhood hepatitis B immunization program and the need for hepatitis B vaccine birth dose in Sierra Leone, 2018. Vaccine. 2022. PMID: 35361502. doi:10.1016/j.vaccine.2022.03.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。